Sedation and Acute Encephalopathy in a Pediatric Patient Following Ingestion of Delta-8-Tetrahydrocannabinol Gummies
Overview
Authors
Affiliations
BACKGROUND Delta-8 tetrahydrocannabinol (delta-8 THC) is an isomer of delta-9-tetrahydrocannabinol (delta-9 THC), the primary psychoactive cannabinoid in the marijuana plant. Typically found at lower concentrations in marijuana, delta-8 THC exhibits psychoactive properties similar to delta-9 THC. Products containing delta-8 THC are readily available across the US and currently there is a lack of available confirmatory testing specific to delta-8 THC as there is cross-reactivity to other naturally occurring cannabinoids in standard immunoassays. Pediatric exposures to this substance are on the rise. CASE REPORT We present a case with laboratory confirmation of a previously healthy 2-year-old girl ingesting approximately 15 mg/kg of delta-8 THC gummies. The patient arrived minimally responsive and requiring intubation for encephalopathy. Laboratory confirmation of delta-8 THC exposure is not routinely available with common testing modalities. A urine drug screen preformed in the hospital was positive for delta-9 THC. With the collaboration of the Drug Enforcement Administration's Toxicology Testing Program, detection and confirmation of delta-8 THC was performed in the serum and urine using liquid chromatography-quadrupole time-of-flight mass spectrometry. CONCLUSIONS The prevalence of delta-8 THC-containing products in the illicit drug market is increasing rapidly. Delta-8 THC products are now available in gas stations and in headshops. The clinical presentation of delta-8 THC exposure is similar to known effects of delta-9 THC exposure. These similarities limit the clinicians' abilities to determine the specific substance ingested. Symptomatic and supportive care remains an effective treatment for cannabinoid toxicity.
Singh H, Garg R, Tampi R Cureus. 2025; 17(2):e79621.
PMID: 40008106 PMC: 11853416. DOI: 10.7759/cureus.79621.
Severe Outcomes in Suspected Pediatric Delta-8-THC Exposures.
Ostrowski S, Scanlon M, Barton D, Lynch M, Trautman W J Med Toxicol. 2024; 21(1):89-92.
PMID: 39718684 PMC: 11707218. DOI: 10.1007/s13181-024-01055-4.
Derived psychoactive cannabis product perceptions and use among a sample of US young adults.
LoParco C, Rossheim M, Cui Y, McCready D, Romm K, Wang Y Addict Behav. 2024; 160:108180.
PMID: 39332229 PMC: 11560547. DOI: 10.1016/j.addbeh.2024.108180.
Online Retail of Derived Psychoactive Cannabis Products: Age and Shipping Restrictions.
LoParco C, Tillett K, Berg C, Rossheim M J Adolesc Health. 2024; 75(2):249-253.
PMID: 38864789 PMC: 11257780. DOI: 10.1016/j.jadohealth.2024.05.004.
Masilamani M, Leff R, Kawai Y Front Toxicol. 2024; 6:1371651.
PMID: 38784384 PMC: 11112079. DOI: 10.3389/ftox.2024.1371651.